VGNX -- Variagenics, Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VGNX -- Variagenics, Inc.

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Miljenko Zuanic who wrote (74)	10/20/2001 12:52:28 AM
From: keokalani'nui	Read Replies (1) of 269

>>There is no therapy based on EGF (small molecules or antibodies) without ski rash as side effects. It indicate that drug is fairly distributed and it reach all part of the body. << Yes, but from what I hear C225 correlates best on those who get skin rash. Some thought it was the chimeric portion, but the smart ones said it was the secondary immune response that coincided with its effectiveness. That is why I thought maybe 4 for 4 skin rash was good news for abgx. Is BS? My statement was a long shot and shows that a little knowledge is a dangerous thing. CI-1033 caught the eye of the invited abstracts, but I did not see anything that made me think "home run". In fact I was dissapointed in a lot (including c225 for pancreatic and iressa for other than nsclc). Do I show my ignorance? Wilder

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next